Back to all Current clinical trials
Back to all Current clinical trials
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis.
What you need to know
Who can take part?
- 18 -75
- BMI 25-50
- diagnosed with liver scarring (fibrosis)
- Exclusion
- Chronic liver diseases other than MASH
- MASH stage 4 (cirrhosis)
- Uncontrolled T2DM (ok if controlled) or T1DM
What is involved for me?
You will be assigned to pegozafermin or placebo subcutaneous injections (2 in 3 chance of drug) 1 or 2 weekly. Will have regular check ups every 2-3 months. The first 12 week screening will involve health checks including scans and possible liver biopsy.
